ZNC-3 is under clinical development by Zentalis Pharmaceuticals and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ZNC-3’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ZNC-3 overview

ZNC-3 is under development for the treatment solid tumors including relapsed or refractory osteosarcoma, epithelial ovarian carcinoma, fallopian tube, peritoneal carcinoma, pancreatic cancer, recurrent uterine serous carcinoma (USC), metastatic colorectal cancer, metastatic ovarian cancer, glioblastoma multiforme and triple-negative breast cancer. It is administered orally as a tablet. The drug candidate acts by targeting WEE1.

It was also under development for the treatment of metastatic advanced breast cancer and non-small cell lung carcinoma.

Zentalis Pharmaceuticals overview

Zentalis Pharmaceuticals formerly Zentalis Pharmaceuticals LLC, is a biopharmaceutical company that discovers and develops small molecule drugs to treat cancers. It is investigating its lead product candidate ZN-c3, a WEE1 inhibitor against uterine serous carcinoma, solid tumors, osteosarcoma, and ovarian cancer. The company is also evaluating ZN-c5, an oral SERD (selective estrogen receptor degrader) for the treatment of breast cancer; ZN-d5, a BCL-2 (B-cell lymphoma 2) inhibitor targeting hematologic malignancies; and ZN-e4, an EGFR (epidermal growth factor receptor) inhibitor to treat non-small cell lung carcinoma. Zentalis Pharmaceuticals utilizes its integrated discovery engine to identify and develop oncology therapies. The company works in collaboration with Pfizer Inc, Mayo Clinic and SciClone Pharmaceuticals Inc, among others. Zentalis Pharmaceuticals is headquartered in New York, the US.

For a complete picture of ZNC-3’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.